MedTrace Logo

Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

NCT07651475 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-06-16

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of the Beach regimen on relapsed/refractory acute myeloid leukemia

Conditions

  • R/R AML

Interventions

DRUG

BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, Chidamide, and G-CSF

BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, chidamide, and G-CSF

Sponsors & Collaborators

  • Liping Dou

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2026-03-31
Completion
2027-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07651475 on ClinicalTrials.gov